Short-Term Opioid Withdrawal Using Buprenorphine: Findings and Strategies from a NIDA Clinical Trials Network (CTN) Study
The Short-term Opioid Withdawal Using Buprenorphine (Bup Detox) Blending Team designed a training package to instruct treatment providers on the administration of aBup Detox Brochure Cover unique,13-day Buprenorphine taper intervention for opioid dependent patients. Research conducted in both inpatient and outpatient settings by the NIDA Clinical Trials Network demonstrated that, in contrast with the clonidine treatment group, patients receiving Buprenorphine provided more opioid-negative urine samples upon completion of the intervention. This training assumes some basic prior information about what Buprenorphine is and how it is used.
Buprenorphine Detox Blending Team Members
NIDA/ NDAT CTN
- Gregory Brigham, Ph.D. - Maryhaven Community Treatment Program
- Judith Harrer, Ph.D. - VA Medical Center
- Dennis McCarty, Ph.D. - Oregon Health and Science University
SAMHSA/CSAT-ATTC
- Thomas Freese, Ph.D. - Pacific Southwest ATTC (Chair)
- Beth Rutkowski, M.P.H. - Pacific Southwest ATTC
- Kay Gresham-Morrison, LCSW, ACSW - Southeast ATTC
- Susan Storti, Ph.D., RN - ATTC of New England